Savara Inc. Showcases aPAP on Lifetime TV’s The Balancing Act

Savara Inc. SVRA, a company dedicated to developing treatments for rare respiratory diseases, announced that a new episode of The Balancing Act^® has aired on Lifetime TV. This episode focuses on autoimmune Pulmonary Alveolar Proteinosis (aPAP) and features the personal story of a patient navigating this rare disease. Insight from Dr. Bruce Trapnell, a prominent figure in the field and the International Coordinating Investigator for Savara’s IMPALA-2 Phase 3 clinical trial, enriches the episode.

Viewers can delve into the real-life account of a patient’s diagnostic journey, which emphasizes the challenges of managing aPAP and the urgent need for better treatment options. A replay is available at https://bit.ly/480OPyy.

“We are pleased to partner with The Balancing Act to highlight aPAP, a rare respiratory disease with no currently approved treatments in the U.S. or Europe,” said Matt Pauls, Chair and CEO of Savara. “By raising awareness about the early signs and symptoms of aPAP and the non-invasive blood test available for diagnosis, we hope to help patients receive timely diagnosis and treatment. Our commitment to the aPAP community is steadfast as we strive to offer effective therapies.”

Savara plans to submit its Biologics License Application (BLA) for molgramostim in the first half of 2025 to the U.S. Food and Drug Administration (FDA).

Understanding aPAP

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare lung condition that leads to a buildup of surfactant in lung alveoli, the tiny air sacs responsible for gas exchange. Normally, this surfactant is cleared by immune cells called alveolar macrophages, which require stimulation from granulocyte-macrophage colony-stimulating factor (GM-CSF) to operate effectively. However, in patients with aPAP, antibodies neutralize GM-CSF, preventing these macrophages from clearing surfactant. The result is a significant accumulation, compromising breathing and leading to symptoms like shortness of breath and fatigue. In serious cases, patients may face complications such as lung fibrosis or the need for a lung transplant.

About Savara

Savara is focused on rare respiratory diseases and is advancing its lead program, molgramostim inhalation solution, which is currently in Phase 3 trials for aPAP. This drug is delivered through an investigational eFlow^® Nebulizer System (PARI Pharma GmbH). With a management team experienced in rare pulmonary diseases, Savara aims to meet critical patient needs and drive its candidates toward approval. Additional information can be found at www.savarapharma.com. Follow on Twitter at @SavaraPharma and LinkedIn at www.linkedin.com/company/savara-pharmaceuticals/.

About Behind the Mystery™

Behind the Mystery™ is a series featured on The Balancing Act^® that covers rare and genetic diseases. It provides clear explanations of complex issues presented by leading experts and fosters connections with organizations and pharmaceutical companies to amplify patient voices. Viewers can watch Behind the Mystery weekdays at 7:30 a.m. (ET/PT) on Lifetime^® and access previous episodes at TheBalancingAct.com/rare.

Cautionary Note Regarding Forward-Looking Statements

Savara emphasizes that statements in this press release that are not historical facts are forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements, which often use words like “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” reflect Savara’s current expectations and involve uncertainties. Factors that may lead to different results include the challenges in developing and seeking regulatory approval for molgramostim, compliance with regulatory authorities, economic changes, and the resources available for operations. For a detailed view of risks and uncertainties, visit our SEC filings, including the recent Form 8-K, Form 10-K, and Form 10-Q. Readers should not rely excessively on forward-looking statements, which are valid only as of their respective dates. Savara has no obligation to update these statements unless legally required.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241022563937/en/